Switching to Symtuza for HIV Maintains High Virologic Suppression Without Drug Resistance

By Marie Rosenthal

SAN FRANCISCO—Adults with HIV who are virologically suppressed maintained that suppression and low virologic failure after switching to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) (Symtuza, Janssen Pharmaceuticals), according to a new report. 

The researchers reported 96-week data from the ongoing phase 3 EMERALD study, an international multicenter randomized, open-label, parallel-group, noninferiority study evaluating the efficacy and safety